Ureteral Stent-Related Symptoms and Pharmacotherapy: A Brief Narrative Review.
drugs
pharmacotherapy
stent-related symptoms
ureteral stents
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
03
04
2023
accepted:
14
07
2023
medline:
11
9
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
ppublish
Résumé
The purpose of this article is to review the effects of different types of pharmacotherapy on symptoms that affect the quality of a patient's life after stent insertion. A thorough Medline/PubMed nonsystematic review was conducted from 1987 to January 2023, using the terms: "pigtail" OR "ureteral stents" AND "lower urinary tracts symptoms" OR "LUTS" AND "pharmacotherapy" OR "drugs". Relevant studies conducted in humans and reported in English language were included. The available reviews and articles associating the use of drugs with stent-related symptoms (SRS) provide conflicting results. Most of them show a clear benefit of alpha blockers, particularly alfuzosin, on treating urinary SRS, and hence there is a strong recommendation for the use of alpha blockers for the treatment of SRS in the guidelines of the European Association of Urology. Anticholinergics and mirabegron have shown a significant benefit in dealing with irritative bladder symptoms. In contrast, the findings for combination therapies are contradictory, with some studies showing that combination therapy is no superior to monotherapy with regards to most of the subsets of the Ureteral Stent Symptom Questionnaire (USSQ), whereas others present a clear benefit of combination therapies, specifically silodosin and solifenacin, in treating stent-associated lower urinary tract symptoms (LUTS), in comparison with any other type of monotherapy or combination therapy. Many studies suggest that some categories of pharmacotherapy, such as alpha blockers, can alleviate SRS. However, there is conflicting evidence concerning most other types of medical treatment. Randomized trials with the largest number of patients are needed to investigate the effectiveness of novel approaches on SRS.
Substances chimiques
Solifenacin Succinate
KKA5DLD701
Adrenergic alpha-Antagonists
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1091-1100Informations de copyright
© 2023 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Références
Finney RP. Experience with new double J ureteral catheter stent. J Urol. 1978;120(6):678-681. https://doi.org/10.1016/s0022-5347(17)57326-7
Hepperlen TW, Mardis HK, Kammandel H. Self-retained internal ureteral stents: a new approach. J Urol. 1978;119(6):731-734. https://doi.org/10.1016/s0022-5347(17)57613-2
Beiko DT, Knudsen BE, Denstedt JD. Advances in ureteral stent design. J Endourol. 2003;17(4):195-199. https://doi.org/10.1089/089277903765444294
Dellis A, Joshi HB, Timoney AG, Keeley FX Jr. Relief of stent related symptoms: review of engineering and pharmacological solutions. J Urol. 2010;184(4):1267-1272. https://doi.org/10.1016/j.juro.2010.06.043
Liu Q, Liao B, Zhang R, et al. Combination therapy only shows short-term superiority over monotherapy on ureteral stent-related symptoms - outcome from a randomized controlled trial. BMC Urol. 2016;16(1):66. https://doi.org/10.1186/s12894-016-0186-y
Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG. Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002;59(4):511-516. https://doi.org/10.1016/s0090-4295(01)01644-2
Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology. 2006;67(1):35-39. https://doi.org/10.1016/j.urology.2005.07.038
Nazim SM, Ather MH. Alpha-blockers impact stent-related symptoms: a randomized, double-blind, placebo-controlled trial. J Endourol. 2012;26(9):1237-1241. https://doi.org/10.1089/end.2012.0036
Lamb AD, Vowler SL, Johnston R, Dunn N, Wiseman OJ. Meta-analysis showing the beneficial effect of α-blockers on ureteric stent discomfort. BJU Int. 2011;108(11):1894-1902. https://doi.org/10.1111/j.1464-410X.2011.10170.x
Liu S, Yu Y, Gao Y, Yang X, Pang Z. Decreased urinary glycosaminoglycan excretion following alfuzosin treatment on ureteral stent-related symptoms: a prospective, randomized, placebo-controlled study. Urolithiasis. 2016;44(2):185-190. https://doi.org/10.1007/s00240-015-0810-4
Mokhtari G, Shakiba M, Ghodsi S, Farzan A, Heidari Nejad S, Esmaeili S. Effect of terazosin on lower urinary tract symptoms and pain due to double-J stent: a double-blind placebo-controlled randomized clinical trial. Urol Int. 2011;87(1):19-22. https://doi.org/10.1159/0003855
Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol. 2009;23(11):1913-1917. https://doi.org/10.1089/end.2009.0173
Wang CJ, Huang SW, Chang CH. Effects of tamsulosin on lower urinary tract symptoms due to double-J stent: a prospective study. Urol Int. 2009;83(1):66-69. https://doi.org/10.1159/000224871
Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res. 2009;37(3):147-152. https://doi.org/10.1007/s00240-009-0182-8
Zhang L, Li J, Pan M, Han W, Liu S, Xiao Y. Doxazosin oral intake therapy to relieve stent - related urinary symptoms and pain: a prospective, randomized, controlled study. Int Braz J Urol. 2016;42(4):727-733. https://doi.org/10.1590/S1677-5538.IBJU.2015.0570
Sahin A, Yildirim C, Yuksel OH, Urkmez A. Treatment of ureteral catheter related symptoms; mirabegron versus tamsulosin/solifenacin combination: a randomized controlled trial. Tratamiento de los sintomas relacionados con los catéteres: mirabegon vs tamsulosina-solifenacina en combinación: un estudio prospectivo randomizado. Arch Esp Urol. 2020;73(1):54-59.
Abdelhamid MH, Zayed AS, Ghoneima WE, et al. Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms. World J Urol. 2017;35(8):1261-1268. https://doi.org/10.1007/s00345-016-1988-y
Hekal IA. Drug treatment of bothersome lower urinary tract symptoms after ureteric JJ-stent insertion: a contemporary, comparative, prospective, randomised placebo-controlled study, single-centre experience. Arab J Urol. 2016;14(4):262-268. Published 2016 Sep 28. https://doi.org/10.1016/j.aju.2016.08.004
Yavuz A, Kilinc MF, Aydin M, Ofluoglu Y, Bayar G. Does tamsulosin or mirabegron improve ureteral stent-related symptoms? A prospective placebo-controlled study. Low Urin Tract Symptoms. 2021;13(1):17-21. https://doi.org/10.1111/luts.12320
El-Nahas AR, Tharwat M, Elsaadany M, Mosbah A, Gaballah MA. A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. World J Urol. 2016;34(7):963-968. https://doi.org/10.1007/s00345-015-1704-3
Maldonado-Avila M, Garduno-Arteaga L, Jungfermann-Guzman R, et al. Efficacy of tamsulosin, oxybutynin, and their combination in the control of double-j stent-related lower urinary tract symptoms. Int Braz J Urol. 2016;42(3):487-493. https://doi.org/10.1590/S1677-5538.IBJU.2015.0186
Bhattar R, Tomar V, Yadav SS, Dhakad DS. Comparison of safety and efficacy of silodosin, solifenacin, tadalafil and their combinations in the treatment of double-J stent- related lower urinary system symptoms: a prospective randomized trial. Turk J Urol. 2018;44(3):228-238. https://doi.org/10.5152/tud.2018.50328
Sivalingam S, Streeper NM, Sehgal PD, Sninsky BC, Best SL, Nakada SY. Does combination therapy with tamsulosin and tolterodine improve ureteral stent discomfort compared with tamsulosin alone? A double-blind, randomized, controlled trial. J Urol. 2016;195(2):385-390. https://doi.org/10.1016/j.juro.2015.08.104
Ragab M, Soliman MG, Tawfik A, et al. The role of pregabalin in relieving ureteral stent-related symptoms: a randomized controlled clinical trial. Int Urol Nephrol. 2017;49(6):961-966. https://doi.org/10.1007/s11255-017-1561-7
Gupta M, Patel T, Xavier K, et al. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol. 2010;183(2):598-602. https://doi.org/10.1016/j.juro.2009.10.021
Kuyumcuoglu U, Eryildirim B, Tuncer M, Faydaci G, Tarhan F, Ozgül A. Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms. Can Urol Assoc J. 2012;6(6):E234-E237. https://doi.org/10.5489/cuaj.10143
Lee SJ, Yoo C, Oh CY, et al. Stent position is more important than α-blockers or anticholinergics for stent-related lower urinary tract symptoms after ureteroscopic ureterolithotomy: a prospective randomized study. Korean J Urol. 2010;51(9):636-641. https://doi.org/10.4111/kju.2010.51.9.636
Giannarini G, Keeley FX Jr, Valent F, et al. Predictors of morbidity in patients with indwelling ureteric stents: results of a prospective study using the validated Ureteric Stent Symptoms Questionnaire. BJU Int. 2011;107(4):648-654. https://doi.org/10.1111/j.1464-410X.2010.09482.x
Cubuk A, Yanaral F, Ozgor F, et al. Comparison of 4.8 Fr and 6 Fr ureteral stents on stent related symptoms following ureterorenoscopy: a prospective randomized controlled trial. Kaohsiung J Med Sci. 2018;34(12):695-699. https://doi.org/10.1016/j.kjms.2018.07.001
Riedl CR, Witkowski M, Plas E, Pflueger H. Heparin coating reduces encrustation of ureteral stents: a preliminary report. Int J Antimicrob Agents. 2002;19(6):507-510. https://doi.org/10.1016/s0924-8579(02)00097-3
Ahallal Y, Khallouk A, El Fassi MJ, Farih MH. Risk factor analysis and management of ureteral double-j stent complications. Rev Urol. 2010;12(2-3):e147-e151.
Betschart P, Zumstein V, Piller A, Schmid HP, Abt D. Prevention and treatment of symptoms associated with indwelling ureteral stents: a systematic review. Int J Urol. 2017;24(4):250-259. https://doi.org/10.1111/iju.13311
El-Nahas AR, El-Assmy AM, Shoma AM, Eraky I, El-Kenawy MR, El-Kappany HA. Self-retaining ureteral stents: analysis of factors responsible for patients' discomfort. J Endourol. 2006;20(1):33-37. https://doi.org/10.1089/end.2006.20.33
Lee YJ, Huang KH, Yang HJ, Chang HC, Chen J, Yang TK. Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis. 2013;41(3):247-252. https://doi.org/10.1007/s00240-013-0554-y